An interventional study of Unilateral Active taVNS and Bilateral Sham taVNS in Voice Quality, sponsored by Sinop University. Not yet recruiting. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Sinop University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to investigate the immediate effects of transcutaneous auricular vagus nerve stimulation (taVNS) on voice characteristics and autonomic function in healthy adults.
A total of 36 healthy adults aged 18-30 years will participate in this randomized, sham-controlled, three-period crossover trial. Each participant will receive three interventions in a randomized order: unilateral active taVNS, bilateral active taVNS, and sham stimulation. Each intervention will last 20 minutes, with at least seven days between visits.
Voice characteristics will be evaluated before and after each intervention using acoustic analysis. The primary outcome will be shimmer, a measure of variation in voice amplitude. Secondary outcomes will include jitter, harmonics-to-noise ratio, and fundamental frequency. Perceived vocal effort, heart rate, and pulse rate variability will also be assessed.
The study will compare the immediate effects of unilateral, bilateral, and sham stimulation on voice stability and explore possible relationships between voice changes and autonomic responses.
This prospective, randomized, sham-controlled, three-period crossover trial will investigate the acute effects of unilateral and bilateral transcutaneous auricular vagus nerve stimulation (taVNS) on acoustic voice parameters and autonomic function in healthy adults.
Thirty-six participants aged 18-30 years will be allocated to one of six intervention sequences (ABC, ACB, BAC, BCA, CAB, or CBA). Each participant will complete three intervention visits separated by a washout period of at least seven days.
The intervention conditions will include: (A) unilateral active stimulation of the left cymba conchae, (B) bilateral active stimulation of the cymba conchae, and (C) bilateral sham stimulation applied to the earlobes with an initial brief sensory stimulation followed by gradual reduction of current to zero. Stimulation will be delivered using Nurosym devices at 20 Hz and 200 μs for 20 minutes. Active stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.
Acoustic voice assessment will involve three recordings of sustained /a/ phonation before and after each intervention. Recordings will be analyzed using Praat software. Shimmer (%) will be the primary outcome, while jitter (%), harmonics-to-noise ratio (dB), and fundamental frequency (Hz) will be secondary outcomes.
Perceived vocal effort will be assessed using a 100-mm visual analogue scale. Autonomic responses will be evaluated using pulse rate variability measurements obtained with the Polar Verity Sense device, including RMSSD, SDNN, and mean heart rate.
Primary analyses will use linear mixed-effects models to compare changes across intervention conditions while accounting for repeated measurements and study periods. Adverse events and stimulation tolerability will be monitored throughout the study.
Sinop University is the lead sponsor of 35 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Unilateral active taVNS, followed by bilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.
Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS
Unilateral active taVNS, followed by bilateral sham stimulation, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.
Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS
Bilateral active taVNS, followed by unilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.
Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS
Bilateral active taVNS, followed by bilateral sham stimulation, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.
Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS
Bilateral sham stimulation, followed by unilateral active taVNS, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.
Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS
Bilateral sham stimulation, followed by bilateral active taVNS, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.
Device: Unilateral Active taVNS · Device: Bilateral Sham taVNS
Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.
Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.
Change in Shimmer (%)
Shimmer (%) will be measured using Praat software from three sustained /a/ phonations. The stable middle 3-second segment of each recording will be analyzed, and the mean of three measurements will be used. Change will be calculated as post-intervention minus baseline shimmer.
Time frame: At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.
Change in Jitter (%)
Change in cycle-to-cycle fundamental frequency variation, measured using Praat software from three sustained /a/ phonations.
Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Harmonics-to-Noise Ratio (dB)
Change in voice harmonic-to-noise ratio, measured using Praat software from three sustained /a/ phonations.
Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Fundamental Frequency (Hz)
Change in mean fundamental frequency (F0), measured using Praat software from three sustained /a/ phonations.
Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Perceived Vocal Effort (mm)
Change in perceived vocal effort assessed using a 100-mm visual analogue scale (VAS), where higher scores indicate greater perceived vocal effort.
Time frame: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in RMSSD (ms)
Change in the root mean square of successive differences (RMSSD), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.
Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
Change in SDNN (ms)
Change in the standard deviation of normal-to-normal pulse intervals (SDNN), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.
Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
hange in Mean Heart Rate (bpm)
Change in mean heart rate measured using Polar Verity Sense during 5-minute recordings.
Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
Change in LF/HF Ratio
Exploratory analysis of the low-frequency to high-frequency power ratio derived from pulse rate variability recordings.
Time frame: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
No study locations are listed for this record.
Plan to share: No — Individual participant data will not be shared with external researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form in scientific publications.
Start is estimated for Nov 2026; primary completion for Jan 2027, 1 month later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sinop University